Closed intravenous administration of gonadotropin-releasing hormone: safety of extended peripheral intravenous catheterization

Obstet Gynecol. 1989 Aug;74(2):267-70.


The use of pulsatile gonadotropin-releasing hormone is an effective means of inducing ovulation, but requires prolonged intravenous (IV) or subcutaneous administration. We hypothesized that the use of self-contained infusion pumps using fluids maintained in a closed system would permit safe peripheral IV administration of gonadotropin-releasing hormone, and possibly other hormones, over prolonged intervals. Thirty-eight female patients undergoing pulsatile IV gonadotropin-releasing hormone therapy were followed for 1958 catheter days (230 catheters). Catheters were removed for signs of local inflammation, at the completion of a treatment episode or, initially, at routine intervals of 7-10 days. There were no episodes of fever (temperature over 37.5C) and three episodes of local inflammation. The incidence of significant catheter-tip cultures was 11%, and none were associated with local inflammation. There were four positive blood cultures (2%), none associated with local or systemic signs of infection. We conclude that the use of a closed system of prolonged peripheral IV cannulation is relatively safe when combined with fastidious care of the catheter site and careful outpatient monitoring for long-term administration of pulsatile gonadotropin-releasing hormone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bacteria / isolation & purification
  • Bacterial Infections / etiology
  • Catheters, Indwelling / adverse effects
  • Equipment Contamination
  • Female
  • Forearm / blood supply
  • Humans
  • Infusion Pumps* / adverse effects
  • Infusions, Intravenous / adverse effects
  • Ovulation Induction / methods*
  • Pituitary Hormone-Releasing Hormones / administration & dosage*


  • Pituitary Hormone-Releasing Hormones